Veradermics, Incorporated (MANE) is a dermatologist-founded, late clinical-stage biopharmaceutical company that went public on the NYSE in February 2026 at $17.00 per share. Because the company is pre-revenue, its valuation is driven almost entirely by clinical progress and the market opportunity for its lead asset, an oral, non-hormonal, extended-release minoxidil called VDPHL01 being developed for pattern hair loss.
The $180 central target is a calculated mean, not an official published consensus. Averaging seven current analyst price targets — $175 (Citi), $150 (Leerink Partners), $182 (Jefferies), $172 (Needham), $170 (LifeSci Capital), and $204 each from B. Riley and UBS — produces about $179.57, rounded to $180. The low-to-high range of $150 to $204 reflects genuine disagreement about how much of VDPHL01's multi-billion-dollar peak-sales potential is already reflected in the share price.
Analysts are uniformly constructive: all seven tracked targets carry Buy or Outperform ratings, and services such as S&P Global and TipRanks describe the consensus as Strong Buy. Bullish cases emphasize a first-in-decades non-hormonal oral option for hair loss, while the more cautious $150 target reflects concern that the stock has already run far on positive data. One outlier sell-side shop, Weiss Ratings, has published a Sell rating, underscoring that views are not unanimous.
At a closing price of $148.44, reaching $180 requires roughly a 21% gain — a substantial move, though far smaller than the stock's roughly 350% year-to-date advance from its $32.00 52-week low. Shares sit just below the 52-week high of $152.82, meaning the path toward $180 begins by clearing that prior peak and establishing new highs.
The route would most plausibly run through continued execution on VDPHL01, including regulatory filings and potential approval, rather than near-term financial results. The company reported a third-quarter net loss of about $21.0 million and held roughly $798.4 million in cash, cash equivalents, and marketable securities as of September 30, 2026, which management says funds operations into 2030. With no approved product, revenue remains minimal, so the story hinges on clinical and regulatory milestones.
Shares trade just below the 52-week high of $152.82, which is the immediate resistance zone; a decisive break above it would leave the stock in price discovery. The 50-day moving average near $118.66 and the 200-day moving average near $97.43 mark progressively deeper support, while the $32.00 IPO-era low and the $17.00 offering price frame how far the stock has already traveled. Given the rapid ascent, the technical structure suggests that any pullback toward the 50-day average would be a key level for investors to watch.
Analyst price targets typically reflect a roughly 12-month research horizon, though individual firms may vary. For a clinical-stage company, the relevant catalysts are not quarterly earnings but rather regulatory updates, additional trial data, and analyst revisions. Investors should watch for any FDA filing or approval timelines for VDPHL01, updates on secondary pipeline programs, changes in cash burn, and any new price-target changes from the covering firms. Macro factors such as interest rates matter less here than biotech sentiment and sector risk appetite.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a fast-moving name like MANE, these signals can help traders discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual screening alone. Explore the signals to see how AI is reading the current tape across the broader market.
The $180 central target is a calculated average of seven Buy-rated analyst price targets ranging from $150 to $204, implying about a 21% gain from the $148.44 close. Reaching it would depend primarily on continued execution and regulatory progress for VDPHL01, supported by strong Phase 3 data and a deep cash runway. The principal obstacles are a steep valuation for a pre-revenue company, the possibility of approval delays, and meaningful analyst disagreement about fair value. The path is plausible but not assured; investors should focus on regulatory milestones and analyst revisions rather than any single price figure.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.